Gene therapy safety check: luxturna registry wraps up
NCT ID NCT03597399
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This completed study tracked 87 patients who received Luxturna gene therapy for a rare inherited eye condition that causes blindness. Researchers monitored side effects and pregnancy outcomes for up to 5 years after treatment. The goal was to gather real-world safety data, not to test if the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
voretigene neparvovec (Luxturna) gene therapy
What this could lead to
If successful, this registry confirms the long-term safety of Luxturna, supporting its continued use for this rare blinding condition.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove effectiveness. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONFIRMED BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bascom Palmer Eye Institute
Miami, Florida, 33136, United States
-
Casey Eye Institute
Portland, Oregon, 97239, United States
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Cullen Eye Institute
Houston, Texas, 77030, United States
-
Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
-
Massachusetts Eye and Ear Institute
Boston, Massachusetts, 02114, United States
-
Scheie Eye Institute
Philadelphia, Pennsylvania, 19104, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States